Document is current
Any future updates will be listed below
-
Authors
Baccon, Domitilla https://orcid.org/0009-0002-3253-232X
Atallah-Yunes, Suheil Albert https://orcid.org/0000-0003-3380-5326
Hampel, Paul J. https://orcid.org/0000-0003-1292-3024
Roeker, Lindsey E.
Kenderian, Saad S. https://orcid.org/0000-0003-2767-3830
Muchtar, Eli https://orcid.org/0000-0003-2210-2174
Kay, Neil E. https://orcid.org/0000-0002-5951-5055
Koehler, Amber B.
Behnken, Amy L.
Wagner, Catherine C.
Johnston, Patrick B.
Nowakowski, Grzegorz S. https://orcid.org/0000-0002-6955-9393
Habermann, Thomas M. https://orcid.org/0000-0003-3532-9132
Hilal, Talal https://orcid.org/0000-0001-8249-4128
Tsang, Mazie
Leis, Jose F.
Rosenthal, Allison C.
Parrondo, Ricardo D. https://orcid.org/0000-0002-9314-9933
Tun, Han W.
Shi, Min https://orcid.org/0000-0002-5741-4293
King, Rebecca L.
He, Rong https://orcid.org/0000-0001-6116-8163
Parikh, Sameer A. https://orcid.org/0000-0002-3221-7314
Wang, Yucai https://orcid.org/0000-0002-1576-8341
- License Information
-
More Information
Article History
Received: 3 October 2025
Revised: 11 November 2025
Accepted: 12 December 2025
First Online: 7 January 2026
Competing interests
: DB: declares no conflicts of interest. PJH: Research funding (to institution): BeOne, AstraZeneca. Consultancy and Honorarium (compensation to the institution): AbbVie. LER: Consulting : AbbVie, Ascentage, AstraZeneca, Beigene, Janssen, Loxo Oncology, Pharmacyclics; Data safety monitoring committee (DSMC) member : Ascentage; CME speaker: DAVA, Curio, Medscape, and PeerView; Minority ownership interest : Abbott Laboratories; Travel support: LOXO oncology, Research funding (to institution): Adaptive Biotechnologies, AstraZeneca, Genentech, AbbVie, Pfizer, Loxo Oncology, Aptose Biosciences, Dren Bio, and Qilu Puget Sound Biotherapeutics. NEK: Advisory Board for : AbbVie, Astra Zeneca, Beigene, Janssen, Pharmacyclics, DSMC (Data Safety Monitoring Committee) for: AstraZeneca, BMS-Celgene, Dren Bio, Research funding : AbbVie, Acerta Pharma, Astra Zeneca, Pharmacyclics/Jannsen, Merck. TH: Research funding (to institution): BeiGene, BMS; Advisory Board: BeiGene. SAP: Research funding : Janssen, AstraZeneca, Merck, and Genentech for clinical studies in which Sameer A. Parikh is a principal investigator. Honoraria : Pharmacyclics, Merck, AstraZeneca, Janssen, BeiGene, Genentech, SoBi, MingSight Pharmaceuticals, Novalgen Limited, Kite Pharma, and AbbVie for Sameer A. Parikh’s participation in consulting activities/advisory board meetings. YW: Research funding (to institution): Incyte, InnoCare, LOXO Oncology, Eli Lilly, MorphoSys, Novartis, Genentech, Genmab, AbbVie, BeiGene, Merck; Advisory board (compensation to institution): Eli Lilly, LOXO Oncology, TG Therapeutics, Incyte, InnoCare, Kite, Jansen, BeiGene, AstraZeneca, Genmab, AbbVie; Consultancy (compensation to institution): InnoCare, AbbVie; Honorarium (to institution): Kite.
: The study was approved by the Mayo Clinic Institutional Review Board. The study was conducted in compliance with the Declaration of Helsinki. Given the retrospective nature of the study, a waiver of consent was obtained.
